{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"KRAScendo 170","nct_id":"NCT05789082","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krascendo-170-nct05789082. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"KRAScendo 170","arms":[{"description":"Participants will be enrolled in different cohorts to receive divarasib (different dose levels will be evaluated) once a day (QD) combined with pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).\n\nDuring the expansion stage, some participants are planned to be randomized to one divarasib combination dose level; other participants are planned to be randomized to another divarasib combination dose level. Divarasib will be given in combination with pembrolizumab.","label":"Cohort A - Combination Dose Finding + Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) QD combined with pembrolizumab 200 mg IV Q3W plus investigator's choice of platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed.","label":"Cohort B - Combination Dose Finding + Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive one dose level of divarasib QD.","label":"Cohort C - Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive one dose level of divarasib QD.","label":"Cohort D - Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-01-29","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":320,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Divarasib","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2032-01-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants with Adverse Events (AEs)","timeFrame":"Baseline until 60 days after the final dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first (up to approximately 5 years)"}],"references":[],"start_date":{"date":"2023-06-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","url":"https://clinicaltrials.gov/study/NCT05789082"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krascendo-170-nct05789082"}